Resolution n°24-2022-e

Amendment to WHO Enabler Grant

Recalling Unitaid Board Resolutions 7-2016-e, 9-2017-e, 17-2017-e, 19-2017-e and 13-2019-e in which the Executive Board approved the commitment of funds of a total amount of up to US$ 46,258,231 to WHO for the Enabler Grant (comprising the HIV and co-infections/co-morbidities, Malaria and Tuberculosis Sub-Grants);

Noting the potential to further strengthen the impact of Unitaid’s investments by leveraging the support of WHO for continuing and recent Board approved projects in the following thirteen Areas for Intervention; and

Also acknowledging the need to extend the funding to WHO to cover support to several Unitaid projects which are already within the existing scope of the three Sub-Grants;

The Board authorizes, subject to availability of funds, the Executive Director to extend the duration of all WHO Enabler Sub-Grants until 31 December 2025 and to commit additional funding of up to US$ 20,000,000 to be allocated across the three Sub-Grants as follows:

- US$ 10,800,000 for HIV and Co-infections/Co-morbidities (previously referenced as HIV/HCV);
- US$ 4,100,000 for Malaria; and
- US$ 5,100,000 for TB.

The additional funding and extension to the grant duration is conditional upon signature of an amendment to the Enabler Grant Memorandum of Understanding between Unitaid and WHO reflecting the new duration and budget ceiling.

Lead Organization: WHO

Revised Project Duration: 1 June 2017 - 31 December 2025

Revised total budget ceiling: US$ 66,258,231

Marisol Touraine
Chair of the Unitaid Executive Board

Date: 19 December 2022